North America Dna Vaccine Market Forecast 2018-2026
The North America DNA vaccine market is predicted to flourish with a CAGR of 42.35% for the forecast period of 2018-2026, generating a market share of $XX million by 2026. The US DNA vaccine market is expected to capture a major share of this market, followed by Canada.
The market is segmented according to the type of technology, applications, and DNA vaccine type. Opportunities like the chance to transform the healthcare landscape, along with the ease of storage and transport of these vaccines are profoundly shaping the market growth. The market is especially gaining popularity in the animal healthcare sector as the vaccines help in the insurance and counteractive action for many veterinary diseases. Also, the ongoing clinical trials for human DNA vaccine are considerably propelling the market ahead.
The leading companies in this market are Merck & Co, Madison Vaccines Incorporated (MVI), Glaxosmithkline Inc, Novartis Ag, Xenetic Biosciences Inc, Astellas Pharma Inc, Inovio Pharmaceuticals Inc and Vical Incorporated.